EUVIMEDEUVIMED entdecken
Open Access

Gestational Weight Gain and Pregnancy Outcomes After GLP-1 Receptor Agonist Discontinuation

Jacqueline Maya, Deepti Pant, Yiran Fu, Kaitlyn James, Carolina Batlle, Sarah Hsu, Diana C Soria-Contreras, Lydia L Shook, Christopher Mow, Marie-France Hivert, Tanayott Thaweethai, Camille E Powe

JAMA · 23.12.2025 · 334 (24) · 2186

DOI: 10.1001/jama.2025.20951 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA, erschienen am 23.12.2025. Verfasst von Jacqueline Maya und 11 weiteren Autor:innen. Beteiligte Einrichtung: Diabetes Unit, Department of Medicine, Massachusetts General Hospital, Boston. Hauptthemen laut MEDLINE: Gestational Weight Gain, Glucagon-Like Peptide-1 Receptor Agonists, Pregnancy Outcome. Die Arbeit wurde bisher 79-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are contraindicated in pregnancy. Discontinuation of GLP-1RAs proximal to pregnancy could affect gestational weight gain and pregnancy outcomes.

Objective

To compare gestational weight gain and pregnancy outcomes with and without exposure to GLP-1RAs before or during early pregnancy. Design, Setting, and Participants Retrospective cohort study of 149 790 singleton pregnancies delivered between June 1, 2016, and March 31, 2025, within a single academic health system. Exposure A GLP-1RA order between 3 years before and 90 days after conception, with propensity score matching of each exposed pregnancy to 3 unexposed pregnancies. Main Outcomes and Measures The primary outcome was gestational weight gain. Secondary outcomes were excess gestational weight gain, large and small for gestational age birth weight, birth weight percentile for gestational age and sex, birth length, preterm delivery, cesarean delivery, gestational diabetes, and hypertensive disorders of pregnancy.

Results

Among 149 790 pregnancies during the study period, 1792 (448 exposed and 1344 unexposed) were matched for the primary analysis. Exposed pregnancies had mean maternal age of 34.0 years (SD, 4.7 years) and prepregnancy body mass index of 36.1 (SD, 6.5; calculated as weight in kilograms divided by height in meters squared); 378 of 448 (84%) had obesity and 104 of 448 (23%) had preexisting diabetes; 136 (30%) were Hispanic, 49 (11%) were non-Hispanic Black, and 223 (50%) were non-Hispanic White; and 43 (10%) had public insurance. The GLP-1RA–exposed pregnancies had greater gestational weight gain (mean, 13.7 kg [SD, 9.2]) than propensity score–matched unexposed pregnancies (mean, 10.5 kg [SD, 8.0]), a difference of 3.3 kg (95% CI, 2.3-4.2; P < .001). The GLP-1RA–exposed group had a higher risk of excess gestational weight gain (65% vs 49%; risk ratio [RR], 1.32; 95% CI, 1.19-1.47), greater mean birth weight percentile (58.4% vs 54.8%; difference, 3.6%; 95% CI, 0.2%-6.9%), and higher risk of preterm delivery (17% vs 13%; RR, 1.34; 95% CI, 1.06-1.69), gestational diabetes (20% vs 15%; RR, 1.30; 95% CI, 1.01-1.68), and hypertensive disorders of pregnancy (46% vs 36%; RR, 1.29; 95% CI, 1.12-1.49). There was no difference in birth length, risk of large or small for gestational age birth weight, or cesarean delivery. Conclusions and Relevance In a cohort composed primarily of women with obesity, GLP-1RA use with subsequent prepregnancy or early pregnancy discontinuation was associated with more gestational weight gain and a higher risk of preterm delivery, gestational diabetes, and hypertensive disorders of pregnancy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Gestational Weight GainGlucagon-Like Peptide-1 Receptor AgonistsPregnancy OutcomeAdultFemaleHumansInfant, NewbornPregnancyBirth WeightCesarean SectionDiabetes, GestationalHypertension, Pregnancy-InducedInfant, Small for Gestational AgePremature BirthPropensity ScoreRetrospective StudiesContraindications, DrugObesity

Substanzen

Glucagon-Like Peptide-1 Receptor Agonists

Autor:innen und Institutionen

  • Diabetes Unit, Department of Medicine, Massachusetts General Hospital, Boston.
  • Department of Pediatrics, Massachusetts General Hospital, Boston.
  • Harvard Medical School, Boston, Massachusetts.
  • Massachusetts General Hospital Biostatistics, Boston.
  • Department of Obstetrics and Gynecology, Massachusetts General Hospital, Boston.
  • University of Puerto Rico, School of Medicine, San Juan, Puerto Rico.

Förderung

  • NIDDK NIH HHS

Zitieren

APA

Maya, J., Pant, D., Fu, Y., James, K., Batlle, C., Hsu, S., Soria-Contreras, D. C., Shook, L. L., Mow, C., Hivert, M. F., Thaweethai, T., & Powe, C. E. (2025). Gestational Weight Gain and Pregnancy Outcomes After GLP-1 Receptor Agonist Discontinuation. JAMA, 334(24), 2186. https://doi.org/10.1001/jama.2025.20951

Vancouver

Maya J, Pant D, Fu Y, James K, Batlle C, Hsu S, et al. Gestational Weight Gain and Pregnancy Outcomes After GLP-1 Receptor Agonist Discontinuation. JAMA. 2025;334(24):2186. doi:10.1001/jama.2025.20951

BibTeX
@article{Maya2025,
  author = {Maya, Jacqueline and Pant, Deepti and Fu, Yiran and James, Kaitlyn and Batlle, Carolina and Hsu, Sarah and Soria-Contreras, Diana C and Shook, Lydia L and Mow, Christopher and Hivert, Marie-France and Thaweethai, Tanayott and Powe, Camille E},
  title = {Gestational Weight Gain and Pregnancy Outcomes After GLP-1 Receptor Agonist Discontinuation},
  journal = {JAMA},
  year = {2025},
  volume = {334},
  number = {24},
  pages = {2186},
  doi = {10.1001/jama.2025.20951}
}
Kostenlos starten →